Induction and maintenance infliximab therapy
in children with moderate to severe ulcerative colitis:
Retrospective, multicenter study

Iwańczak, Barbara; Ryżko, Józef; Jankowski, Piotr; Sładek, Małgorzata; Wasilewska, Agata; Szczepanik, Mariusz; Sienkiewicz, Edyta; Szaflarska-Popławska, Anna; Więcek, Sabina; Czaja‐Bulsa, Grażyna; Korczowski, Bartosz; Maślana, Jolanta; Iwańczak, F; Kacperska, Magdalena Justyna

doi:10.17219/acem/35802

Cited by 3 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with those of previous reports. [26][27][28] As for malignancy, our results showed that lymphoma, breast cancer, and gastric cancer were significantly correlated with TNF-alpha inhibitors as a class. Especially, reports of breast cancer were numerous with etanercept.…”

Section: Discussionmentioning

confidence: 71%

<p>Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database</p>

Wakabayashi¹,

Hosohata²,

Oyama³

et al. 2020

TCRM

View full text Add to dashboard Cite

Introduction Concerns over safety profiles of tumor necrosis factor (TNF)-alfa inhibitors have been raised. The purpose of this study was to clarify the adverse events associated with TNF-alfa inhibitors using a spontaneous reporting system database. Materials and Methods A retrospective pharmacovigilance disproportionality analysis was conducted using the Japanese Adverse Drug Event Report (JADER) database. Adverse event reports submitted to the Pharmaceuticals and Medical Devices Agency between 2004 and 2017 were analyzed, and the reporting odds ratio (ROR) and 95% confidence interval (CI) for each adverse event were calculated. Results Among the 34,031 reports of adverse events associated with TNF-alfa inhibitors, 65.8% were women, who were frequently in their 60s (28.2%). Signals were detected for pneumonia (ROR, 5.36; 95% CI, 5.14–5.6), interstitial lung disease (ROR, 2.04; 95% CI, 1.95–2.15), pneumocystis jirovecii pneumonia (ROR, 11.8; 95% CI, 11.1–12.5), and herpes zoster (ROR, 6.4; 95% CI, 5.92–6.91) for TNF-alfa inhibitors as a class. There was variability in their signal strength across individual TNF-alfa inhibitors. Conclusion The strength of the associations of TNF-alfa inhibitors with adverse events is variable, and further studies are required to evaluate the identified signals.

show abstract

Section: Discussionmentioning

confidence: 71%

<p>Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database</p>

Wakabayashi¹,

Hosohata²,

Oyama³

et al. 2020

TCRM

View full text Add to dashboard Cite

show abstract

“…From the multicenter study on the treatment with infliximab of children with Crohn's disease conducted in the years 2004-2013 in Poland, a group of children with fistualas was selected [21,22]. Two hundred twenty one individual patients questionnaires were collected from 10 centers in which the treatment with infliximab was conducted.…”

Section: Methodsmentioning

confidence: 99%

“…In 55 (24.88%) children from this group fistulas were present; in 22.62% -perianal fistulas and in 2.25% -fistulas with other localization. The results of the treatment with infliximab of 153 children with Crohn's disease without fistulas were described in another paper [22]. In this study we analyzed the treatment with infliximab of 50 children with Crohn's disease with simple and complex fistulas.…”

Section: Methodsmentioning

confidence: 99%

“…In all 50 children with Crohn's disease inflammatory changes were localized in the ileum and colon. According to National Health Fund recommendation, the criterion of qualification to the treatment with infliximam program was the presence of fistula independently of Pediatric Crohn's Disease Activity Index), age of patients from 6 to 18 years and failure to respond to previous treatment with antibiotics, immunosuppressive drugs as well as failure of surgical treatment [21]. All the children in our study aged from 9 to 18 years were divided into two groups.…”

Section: Methodsmentioning

confidence: 99%

“…Remission has been defined as the closure of all fistulas which persisted at least during two visits of the patient. National Health Fund therapeutic program of treatment of Crohn's disease with fistulas in children aged 6 to 18 years includes treatment with infliximab in all patients who have not responded to antibiotics, immunosuppressive drugs and surgical treatment regardless to disease activity [21].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Induction and Maintenance Infliximab Therapy for the Treatment of Crohn’s Disease with Perianal Fistulas in Children: Retrospective, Multicenter Study

Iwańczak¹,

Ryżko²,

Jankowski³

et al. 2016

Adv Clin Exp Med

Self Cite

View full text Add to dashboard Cite

Background. Infliximab is a biological drug used for the treatment of Crohn's disease in children. Objectives. The aim of this retrospective study was the estimation of effectiveness and safety of infliximab in the treatment of Crohn's disease with perianal fistulas in children. Material and Methods. Analysis comprised 50 children with Crohn's disease with perianal fistulas aged 9 to 18 years (16 girls and 34 boys) who failed to respond to conventional therapy. The children were divided into two groups: the first group contained 23 children with simple fistulas and the second -27 children with complex fistulas. All children were treated with infliximab, administered in the dose of 5 mg per kilogram of the body mass. In the induction phase infliximab was administered at weeks 0, 2 and 6 and after clinical response in maintenance phase the drug was administered every 8 weeks; together for 12 months. Results. In 76% of children after induction therapy with infliximab and in 71.87% after maintenance therapy the complete closure of fistula occurred. During the first year after the treatment a recurrence of a fistula was observed in 30.43% of the children. In two children anaphylactic shock was observed during injection of infliximab. The remaining children tolerated the drug well. Conclusions. The treatment with infliximab was effective in the majority of fistulazing Crohn's disease and caused the closure of perianal fistula which improved quality of life (Adv Clin Exp Med 2016, 25, 3, 523-530).

show abstract

Dietary Supplementation of Ancientino Ameliorates Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Reducing Inflammation and Oxidative Stress

Liu,

Wang,

Guan

et al. 2023

Nutrients

View full text Add to dashboard Cite

Ancientino, a complex dietary fiber supplement mimicking the ancient diet, has improved chronic heart failure, kidney function, and constipation. However, its effect on ulcerative colitis is unknown. This study explores the impact of Ancientino on colitis caused by dextran sulfate sodium (DSS) and its mechanisms. Data analyses showed that Ancientino alleviated bodyweight loss, colon shortening and injury, and disease activity index (DAI) score, regulated levels of inflammatory factors (tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), interleukin-1 beta (IL-1β), and interleukin 6 (IL-6)), reduced intestinal permeability (d-lactate and endotoxin), fluorescein isothiocyanate–dextran (FITC-dextran), and diamine oxidase (DAO), repaired colonic function (ZO-1 and occludin), and suppressed oxidative stress (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and malondialdehyde (MDA)) in vivo and in vitro. In short, this study demonstrated that Ancientino alleviates colitis and exerts an anticolitis effect by reducing inflammatory response, suppressing oxidative stress, and repairing intestinal barrier function. Thus, Ancientino may be an effective therapeutic dietary resource for ulcerative colitis.

show abstract

Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study

Cited by 3 publications

References 7 publications

<p>Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database</p>

<p>Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database</p>

Induction and Maintenance Infliximab Therapy for the Treatment of Crohn’s Disease with Perianal Fistulas in Children: Retrospective, Multicenter Study

Dietary Supplementation of Ancientino Ameliorates Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Reducing Inflammation and Oxidative Stress

Contact Info

Product

Resources

About